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Abstract
Background—Although hypertension is known to have an adverse impact on health-related 
quality of life (HRQoL) in adults, little is known about the effects of hypertension and use of 
antihypertensive medications on HRQoL in hypertensive children with chronic kidney disease 
(CKD).
Methods—Cross-sectional and longitudinal assessment of impact of elevated blood pressure 
(BP) and antihypertensive medication use on HRQoL scores obtained in children enrolled in the 
Chronic Kidney Disease in Children Study. Blood pressure was measured both manually and by 
ambulatory blood pressure monitoring. HRQoL was assessed with the PedsQL survey.
Results—Study sample included 551 participants with sufficient data for cross-sectional and 
longitudinal analyses. Cross-sectional analysis of presence of prehypertension or hypertension and 
impact on HRQoL found mild associations between elevated BP and HRQoL scores with overall 
PedsQL parent and child scores averaging 79 versus 76.5 and 83 versus 78.5, respectively. 
However, no associations persisted under longitudinal multivariate analysis.
Conclusions—Despite apparent small effects of elevated BP on HRQoL at baseline, no 
association was found between the presence of elevated BP and HRQoL over time in children with 
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mild to moderate CKD. In addition, antihypertensive medication use did not appear to have an 
impact on HRQoL in this population.
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Introduction
Hypertension (HTN) is a common complication in children with chronic kidney disease 
(CKD) and contributes to increased morbidity and mortality in this population [1]. Fifty-four 
percent of children initially enrolled in the Chronic Kidney Disease in Children (CKiD) 
study had elevated blood pressures and/or a history of HTN and current antihypertensive 
medication use [2].
Various co-morbid conditions related to CKD can adversely affect health-related quality of 
life (HRQoL). Children with CKD report poorer overall HRQoL scores and poorer physical, 
school, emotional, and social functioning compared to healthy children [3]. Adult studies 
have shown a reduction in HRQoL in hypertensive patients to be associated with patient 
health comorbidities, awareness of diagnosis, and adverse effects from treatment [4]. For 
example, the African American Study of Kidney Disease and Hypertension (AASK) trial 
showed that African American adults with higher mean arterial pressure, longer duration of 
HTN, a larger number of antihypertensive medications, and more severe CKD had 
significantly lower HRQoL scores [5]. The AASK trial also found that physical aspects of 
quality of life were substantially reduced compared with mental components [5]. Similar 
studies in children are lacking and identifying associations between blood pressure and 
HRQoL in pediatric patients with CKD may be important with respect to targeting 
modifiable factors that can negatively impact these children’s psychosocial development.
The primary aim of this study was to address this gap in the literature by determining if the 
presence of elevated blood pressures (BP), antihypertensive medication use, and/or duration 
of HTN were associated with decreased HRQoL in children with mild to moderate CKD.
Methods
The CKiD study is a multicenter longitudinal, observational cohort study of children with 
glomerular filtration rates (GFR) between 30–90 ml/min/1.73 m2 determined by estimating 
GFR by Schwartz equation or measuring GFR by iohexol infusion at enrollment [6, 7]. 
Iohexol infusion was used to measure 508 GFRs and the remaining 43 GFRs were estimated 
by Schwartz equation [7]. The design and methods of the CKiD study have been previously 
reported [8]. The study protocol was approved by the Institutional Review Boards at all 
participating centers; informed consent and/or assent was obtained according to local 
requirements prior to inclusion in study.
Measurement of casual blood pressure
Casual blood pressure was measured at each CKiD visit (e.g. baseline, 6 months after 
enrollment and then yearly) by auscultation with an aneroid sphygmomanometer (Mabis 
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MedicKit 5, Mabis Healthcare, Waukegan, IL) [2]. Blood pressure was classified according 
to the National High Blood Pressure Educational Program Fourth Report as normotensive 
(BP <90th percentile and <120/80 mmHg), prehypertensive (BP ≥90th and <95th percentile 
or <90th percentile and >120/80 mmHg), or hypertensive (BP ≥95th percentile) [9]. BP index 
was calculated by dividing individual’s measured casual BP by the 95th percentile systolic or 
diastolic BP for age, gender, and height.
Measurement of ambulatory blood pressure
Ambulatory blood pressure monitoring (ABPM) was conducted at study visits done at year 
1, 3, and 5 after baseline using the SpaceLabs 90217 device (SpaceLabs Healthcare, 
Issaquah, WA). Blood pressure measurements were collected every 20 minutes during the 
day and night, and the child and family kept a diary recording wake, sleep, and any 
medications given while wearing the monitor [10]. HTN by ABPM was defined by systolic 
or diastolic BP index >1 (subject’s mean systolic or diastolic BP/95th% BP for gender and 
height) or systolic or diastolic BP load >25% [11].
Measurement of HRQoL
HRQoL was evaluated in all children using the 23-item Parent and Child Report Pediatric 
Inventory of Quality of Life Core Scales (PedsQL™, Version 4.0) [12, 13]. The PedsQL 
assesses the problem frequency within the domains of physical, emotional, social, school, 
and overall functioning. This study focused on HRQoL domains of physical, school, and 
overall functioning. Responses are summed and linearly transformed into a score ranging 
from 0–100, with higher scores suggesting a better HRQoL.
Statistical analysis
Data analysis included cross-sectional description of the sample at the first available study 
visit. To investigate the hypothesized relationship between hypertension and HRQoL domain 
scores in children with CKD, a cross-sectional analysis compared HRQoL scores by 
prehypertensive and hypertensive status defined as either: 1) systolic and/or diastolic BP ≥ 
90th percentile for age, sex, and height, or 2) self-reported diagnosis of hypertension 
combined with current antihypertensive medication use. Similar analysis of ABPM data 
used systolic or diastolic load ≥ 25% in place of BP ≥ 90th percentile. Wilcoxon rank-sum 
tests were used to compare HRQoL scores between groups.
We then utilized longitudinal measurements in the cohort to analyze the impact of a change 
of 0.05 in BP index or 5% in BP load on HRQoL domain scores. For each of the six 
different HRQoL outcomes as measured by PedsQL (Parent and Child Overall, Physical, 
and School), and each of four main predictors of interest (Systolic and Diastolic BP Index 
and ABPM Load), a median regression model was used controlling for potential 
confounders including age, sex, African-American race, Hispanic ethnicity, maternal 
education, low birth weight, height z-score, GFR baseline and annual rate of change, 
duration of CKD, and nephrotic range proteinuria (urine protein to creatinine ratio > 2 mg/
mg).
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To analyze if the presence of HTN or no HTN impacted HRQoL domain scores in children 
with CKD, longitudinal measurements were also performed. Dichotomous HTN was 
interacted with age in order to assess the effect of HTN over time. Additionally, to determine 
whether antihypertensive medications affected HRQoL, a categorical variable for number of 
medications (none, 1, or 2 or more) was included in all models. Confidence intervals were 
obtained by bootstrapping with 2000 replicates at the subject level to account for clustering 
of observations.
Results
Data on blood pressure and quality of life were available for 551 subjects, contributing a 
total of 2,376 visits. Ambulatory blood pressure measurements were available for 396 of 
these subjects, with 673 total visits. Descriptive statistics of subjects at their first visit are 
found in Table 1. A higher number of subjects had a non-glomerular etiology for CKD 
compared to subjects with a glomerular etiology for CKD, 434 (79%) versus 117 (21%) 
subjects, respectively. Of the 548 subjects with known blood pressure status, 384 (69.7%) 
were normotensive with 236 of these subjects on antihypertensive medications; 164 (29.8%) 
had elevated blood pressures with 101 of these subjects on antihypertensive medications; 
and 3 of the 551 subjects were missing blood pressure status (Table 2). At the first visit with 
ABPM data available, 155 (39%) of 396 subjects had either a systolic or diastolic load of 
25% or higher. Of the 551 subjects included in the analysis, 318 (58%) did not have 
complete follow-up, including 172 (31%) renal replacement therapy (dialysis or transplant) 
events, 143 (26%) with loss to regular follow-up (withdrawal, age-out, etc.), and 3 deaths. 
Of the CKiD cohort of 510 subjects with a least one post-baseline visit, 350 of 506 (69%, 4 
with missing data) had a negative GFR annual slope. GFR did decline over the observed 
follow-up period.
Unadjusted cross-sectional analysis of PedsQL scores and hypertensive status suggested 
several statistically significant, though not clinically meaningful, differences between 
hypertensive status (defined, as described above, as elevated BP or self-reported 
hypertension plus BP medication use) and HRQoL scales (Table 3). With casual BP 
measurements, both parent- and child-rated overall HRQoL was lower among hypertensive 
children (p=0.01 and 0.03 respectively), though the magnitude of the difference in median 
scores was minor (3 and 2 points respectively). Parent-rated school HRQoL was a median 10 
points lower among hypertensive children (p=0.003), though this was only 5 points lower for 
child ratings (p=0.052). Neither parent- nor child-rated physical HRQoL was significantly 
lower among hypertensive children. Using the definition of hypertension based on 
ambulatory rather than casual measurements, all three parent-rated scales were lower among 
hypertensive children compared to normotensive children, with the greatest difference on the 
overall scale (84.5 vs. 78, p< 0.001). Children rated themselves lower only on the school 
subscale (75 vs. 65, p=0.007).
Median regression models incorporating longitudinal data where the primary predictor is 
either presence of prehypertension or HTN, defined as systolic and/or diastolic BP ≥ 90th 
percentile, systolic and/or diastolic ABPM load >25%, or self-reported HTN plus use of 
antihypertensive medications, or no presence of HTN. These models did not find a 
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significant relationship between HTN and HRQoL over time (Table 4). Largest effect was 
presence of HTN on Child Physical HRQoL with corresponding decrease in HRQoL of 
12.49 points (95% CI, −21.74 to −2.26).
Median regression models incorporating longitudinal data and continuous rather than 
dichotomous BP measurements did not find a relationship between casual BP index or 
ABPM load on HRQoL (Table 5). For instance, using systolic BP index as the primary 
predictor and parent overall HRQoL as the outcome with covariates listed above, an increase 
of 0.05 in systolic BP index was associated with a corresponding decrease in HRQoL of 
0.24 points (95% CI, −0.93 to 0.41). The largest effect magnitudes were seen on parent and 
child school HRQoL, though no effects reached statistical significance in these adjusted 
models.
At baseline, 339 subjects were on BP medications (see Table 2), including 53% being on an 
angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). 
Median regression analysis did not find any association between number of antihypertensive 
medications used and HRQoL (see Table 6a and 6b).
Discussion
The goal of this study was to determine if elevated BP and/or antihypertensive medication 
use had a negative impact on HRQoL in children with CKD. As opposed to findings in 
studies conducted in hypertensive adults, this analysis in children found that while the 
presence of HTN or history of HTN on antihypertensive medications was associated with 
lower parent and child HRQoL scores, these differences in PedsQL scores were not 
clinically significant, and did not persist over time.
Over the past two decades from 1990 through 2010, the incidence of CKD in children has 
steadily increased, with HTN as a common complication and a potentially modifiable risk 
factor for disease progression [14–16]. End-organ disease, medication adverse effects, and 
labeling phenomenon due to HTN are all factors that may contribute to poorer self-related 
health and reduction in HRQoL [17–19]. Determining what features of CKD and 
cardiovascular disease impact HRQoL is of great interest to better understand how providers 
may customize care to be patient-centered with a focus on psychosocial and emotional 
issues with hopes of improving overall health.
The lack of a relationship between HTN and HRQoL in children with mild to moderate 
CKD may be due to children having fewer limiting physical and cardiovascular co-
morbidities compared to adults. Older adults with cardiovascular disease, including 
congestive heart failure, myocardial infarction, and/or angina, reported lower physical and 
mental health HRQoL scores [4]. Although children with HTN tend not to have as severe 
cardiovascular disease as seen in adults, investigation of predictors of cardiovascular events 
in the CKiD cohort has previously revealed significantly elevated median carotid intima-
media thickness (cIMT) that was 0.02 mm larger (95% confidence interval, 0.01–0.05) 
compared to healthy controls and 17% had LVH [20, 21]. Determination of the impact of 
HTN on end-organ damage in children with CKD and the association with HRQoL is 
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difficult since etiology of findings, such as proteinuria and impaired cognition, are often 
multifactorial.
Symptom burden is another factor that has been shown to negatively impact HRQoL in 
adults with advanced CKD and on dialysis.[22, 23]. To study the impact of symptom burden 
in children with chronic medical conditions, Kim et al classified children into 3 groups, 
those with low-, moderate-, or high-symptoms, and assessed the impact on quality of life 
[24]. Children who reported the most problems with symptoms had the lowest HRQoL 
scores [24]. Roumelioti et al found a strong association between trouble sleeping, low 
energy, and lower HRQoL scores in children with mild to moderate CKD [25]. Similar to 
findings in our analysis, Roumelioti did not find a relationship between HTN, 
antihypertensive medication use, symptom burden, and HRQoL [25]. Whereas chronic HTN 
is often thought to be an asymptomatic condition with a lower symptom burden that may 
have less of an impact on HRQoL, studies in both adults and children suggest this is not the 
case [26, 27]. One pediatric study evaluated 343 hypertensive children without CKD and 
found the majority were not symptom free [28]. Most common symptoms included 
headache, trouble falling asleep, tiredness, chest pain, abdominal pain, school failure, and 
poor concentration [28]. As we did not specifically question participants regarding HTN-
related symptoms, we cannot comment on whether a lack of such symptoms might have 
contributed to a lack of effect of HTN on HRQoL. Alternatively, other CKD-related 
symptoms may dominate, masking the effect of symptoms specific to HTN.
Evaluating if there is an effect of antihypertensive medications on HRQoL is important since 
many children with CKD require medications to adequately control their blood pressure 
within the goal of <90th percentile for age, gender, and height or <130/80, whichever is 
lower [29]. Studies have shown that aggressive control of BP slows the progression of CKD, 
though studies assessing the impact of therapy on HRQoL are lacking [14]. In this study, our 
analysis of subject’s use of antihypertensive medications did not negatively affect child or 
parent HRQoL domain scores. Use of an ACE inhibitor or ARB antihypertensive medication 
is recommended as first line therapy for HTN in children with CKD [17, 29]. More than half 
of the CKID subjects were on an ACE inhibitor or ARB, which tend to have a lower 
symptom burden than other antihypertensive medications, such as beta blockers [19].
Limitations of this study include the observational study design and the fact that the 
population may not be generalizable to all children with mild to moderate CKD. In 
particular, the CKiD cohort racial distribution and cause of CKD may differ from the general 
population of youth with kidney disease. Another limitation of this analysis is that it may not 
be possible to discern an independent effect of HTN on HRQoL due to the many other 
factors that are present in children with CKD. For instance, higher pill burden, poor linear 
growth, poor school functioning have all been associated with lower HRQoL [3, 6, 30]. 
However, the study also has notable strengths, including a large population of children with 
mild to moderate CKD whose blood pressures were measured by casual and ABPM 
measurements and PedsQL scores that were repeated longitudinally.
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Conclusion
No clinically meaningful association was found between presence of elevated blood 
pressures/HTN and decreased HRQoL at baseline or between changes in HTN and HRQoL 
over time in children with mild to moderate CKD. In addition, antihypertensive medication 
use was not associated with decline in HRQoL in this population.
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Table 1
Baseline demographics of subjects
Characteristic Median [IQR] or n (%)
Covariates
Total number of subjects 551
Age, years 11.5 [7.9, 15.1]
Male sex 342 (62%)
African-American 124 (23%)
Hispanic 80 (15%)
Maternal Education
 High School or less 229 (43%)
 Some college 146 (27%)
 College or more 163 (30%)
Low birth weight 101 (19%)
Height z-score −0.7 [−1.4, 0.0]
GFRa, ml/min/1.73 m2 44.6 [33.4, 58.0]
Duration of CKD, years 6.4 [3.1, 10.3]
Glomerular CKD diagnosis 117 (21%)
Nonglomerular CKD diagnosis 434 (79%)
Urine Protein/Creatinine, mg/mg 0.4 [0.2, 1.1]
Urine Protein/Creatinine > 2, mg/mg 69 (13%)
IQR = interquartile range, n = number of subjects,
aGFR = glomerular filtration rate measured by iohexol or estimated by Schwartz equation [7]:
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Table 2
Diagnosis of hypertension, antihypertensive medication use, and baseline blood pressures
Characteristic Median [IQR] or n (%)
Subjects with self-reported diagnosis of hypertension and on antihypertensive medications 242 (45%)
All antihypertensive medication use
 Any 339 (62%)
 ACEi/ARB 292 (53%)
 Other 47 (9%)
Subjects with known BP statusa 548
 Normotensive on BP medications 236 (43%)
 Elevated blood pressures on BP medications 101 (18%)
Blood Pressure
Systolic BP Indexb 0.88 [0.82, 0.94]
Diastolic BP Indexb 0.84 [0.75, 0.94]
Systolic or Diastolic BP percentile ≥ 90 164 (30%)
Systolic ABPM Loadc 11 [3, 30]
Diastolic ABPM Loadc 11 [4, 26]
ABPM Systolic or Diastolic loadc ≥25% 155 (39%)
IQR = interquartile range, n = number of subjects, ACEi = Angiotensin-converting-enzyme inhibitor, ARB = Angiotensin receptor blocker, BP = 
blood pressure,
a
BP status unknown for 3 of the 551 subjects (2 in medication group and 1 in no medications),
b
BP index = casual BP divided by the 95th percentile systolic or diastolic BP for age, gender, and height,
cABPM loads from first available visit.
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Table 3
Baseline comparisons of parent and child HRQoL outcomes by normotensive versus prehypertensive/
hypertensive status
HRQoL Outcome
Casual BP Normotensive (n=242)
Median [IQR]
Casual BP Pre- and Hypertensive (n=309)
Median [IQR] p-value
Parent Overall 79 [66, 90] 76 [62, 87] 0.01
Parent Physical 84 [69, 97] 84 [66, 94] 0.27
Parent School 70 [50, 85] 60 [45, 80] 0.003
Child Overall 79 [68, 88] 77 [65, 84] 0.03
Child Physical 84 [72, 94] 81 [69, 94] 0.16
Child School 70 [55, 80] 65 [50, 75] 0.052
ABPM Normotensive (n=151) ABPM Hypertensive (n=245) p-value
Parent Overall 84.5 [68, 92] 78 [62, 88] 0.0009
Parent Physical 91 [75, 100] 86 [69, 97] 0.009
Parent School 70 [60, 90] 65 [50, 85] 0.005
Child Overall 82 [69, 90] 79 [68, 87] 0.14
Child Physical 84 [72, 94] 84 [75, 94] 0.86
Child School 75 [60, 85] 65 [55, 80] 0.007
HRQoL = Health related quality of life, BP = blood pressure, n = subjects, IQR =
interquartile range, ABPM = ambulatory blood pressure monitoring
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Table 4
Summary of longitudinal median regression models comparing HRQoL by blood pressure status over time
QOL Outcome HTNa or Normotensive (CI) HTNa X Age (CI)
Parent Overall −6.59 (−12.83, 0.43) 0.45 (−0.07, 0.98)
Parent Physical −2.02 (−10.18, 4.85) 0.22 (−0.29, 0.89)
Parent School −9.21 (−20.29, 0.13) 0.46 (−0.20, 1.33)
Child Overall −7.55 (−16.33, 1.90) 0.57 (−0.08, 1.22)
Child Physical −12.49 (−21.74, −2.26) 0.97 (0.26, 1.59)
Child School −6.53 (−18.12, 9.67) 0.46 (−0.71, 1.27)
HRQoL = health related quality of life, HTN = hypertension, CI = confidence interval,
a
HTN = hypertension that includes prehypertension, hypertension, and/or self-reported HTN plus use of antihypertensive medications.
Pediatr Nephrol. Author manuscript; available in PMC 2017 October 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Wong et al. Page 14
Table 5
Summary of longitudinal median regression models comparing HRQoL and continuous blood pressure values 
over time
BP Predictor
HRQoL Outcome Systolic BP Index
a
per 0.05 (CI)
Diastolic BP Indexa
per 0.05 (CI)
Systolic ABPM Load
per 5% (CI)
Diastolic ABPM Load
per 5% (CI)
Parent Overall −0.24 (−0.93, 0.41) −0.39 (−0.81, 0.07) −0.10 (−0.72, 0.39) −0.33 (−0.86, 0.34)
Parent Physical −0.13 (−0.86, 0.66) −0.09 (−0.67, 0.32) 0.22 (−0.48, 0.60) 0.00 (−0.73, 0.63)
Parent School −0.56 (−1.42, 0.46) −0.47 (−1.09, 0.11) −0.45 (−1.23, 0.36) −0.20 (−1.02, 0.53)
Child Overall 0.27 (−0.31, 0.82) −0.12 (−0.52, 0.28) 0.08 (−0.45, 0.40) −0.17 (−0.60, 0.34)
Child Physical 0.13 (−0.55, 0.82) −0.19 (−0.58, 0.33) −0.08 (−0.61, 0.36) −0.13 (−0.72, 0.41)
Child School −0.24 (−1.17, 0.56) −0.50 (−1.12, 0.04) −0.32 (−1.04, 0.17) −0.73 (−1.22, 0.08)
HRQoL = health related quality of life, BP = blood pressure,
a
BP index = casual BP divided by the 95th percentile systolic or diastolic BP for age, gender, and height, CI = confidence interval
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Table 6a
Blood pressure medication usage at baseline and over time regardless of blood pressure status
No BP meds (n) 1 BP med (n) 2 or more BP meds (n)
Baseline (n=551) 38.5% (212) 41.7% (230) 19.8% (109)
All visits (n=2376) 36.0% (855) 44.5% (1058) 19.5% (463)
BP = blood pressure, n = number of subjects
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Table 6b
Effect of blood pressure and number of antihypertensive medication use on HRQoL
Systolic BP Predictor on BP 
medication
HRQoL Outcome
Systolic BP Indexa
per 0.05 1 med (CI)
Systolic BP Indexa
per 0.05 2+ meds (CI)
Systolic Load ABPM
per 5% 1 med (CI)
Systolic Load ABPM
per 5% 2+ meds (CI)
Parent Overall 1.57 (−1.95, 3.84) 0.77 (−4.02, 3.97) 1.81 (−3.89, 6.02) 4.16 (−3.63, 9.56)
Parent Physical 2.14 (−0.72, 5.38) 0.62 (−4.09, 5.41) 4.26 (−0.60, 10.34) 1.53 (−4.72, 10.43)
Parent School 0.22 (−4.27, 3.95) −2.12 (−7.59, 2.96) −1.54 (−8.17, 5.04) 1.48 (−8.51, 9.82)
Child Overall 1.44 (−1.15, 3.43) −1.15 (−4.75, 1.85) 2.03 (−1.43, 6.00) 1.72 (−4.96, 5.93)
Child Physical 2.03 (−0.78, 4.35) −1.79 (−5.47, 1.81) 1.20 (−1.76, 6.87) −0.99 (−5.24, 6.58)
Child School 1.84 (−2.13, 4.70) −0.37 (−6.19, 3.88) −0.98 (−5.27, 6.02) 2.56 (−4.21, 9.65)
Diastolic BP Predictor on BP 
medication
HRQoL Outcome
Diastolic BP Indexa
per 0.05 on 1 med (CI)
Diastolic BP Indexa
per 0.05 2+ meds (CI)
Diastolic Load ABPM
per 5% 1 med (CI)
Diastolic Load ABPM
per 5% 2+ meds (CI)
Parent Overall 1.66 (−1.94, 3.75) 1.10 (−4.25, 3.95) 0.64 (−3.99, 5.56) 4.34 (−4.09, 9.39)
Parent Physical 2.25 (−0.85, 5.30) 0.84 (−4.32, 5.45) 4.26 (−0.71, 10.10) 2.54 (−4.69, 10.56)
Parent School 0.49 (−4.44, 3.72) −2.49 (−7.83, 2.78) −0.89 (−7.90, 5.42) 1.15 (−9.06, 9.98)
Child Overall 1.15 (−1.22, 3.29) −1.44 (−4.64, 1.63) 2.58 (−1.56, 5.88) 0.78 (−5.05, 5.80)
Child Physical 1.74 (−0.91, 4.20) −1.81 (−5.42, 1.83) 1.11 (−1.75, 6.64) −1.42 (−5.65, 6.81)
Child School 1.71 (−2.47, 4.64) −0.87 (−6.19, 3.62) −0.50 (−5.36, 5.72) 2.88 (−4.46, 8.88)
HRQoL = health related quality of life, BP = blood pressure,
aindex = Casual BP divided by the 95th percentile systolic or diastolic BP for age, gender, and height, ABPM = ambulatory blood pressure 
monitoring, CI = confidence interval,
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